Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 1/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 10/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217561 | 0.92 | NPBWR1 (0.42) | CBFBNPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL5221536 | 0.81 | CBFB (0.51) | CBFBNPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL5217809 | 0.80 | CBFB (0.50) | CBFBNPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL5221543 | 0.72 | CBFB (0.41) | CBFBNPBWR1DGAT1KCNH2BACE1 | |
| SCHEMBL5217821 | 0.72 | CBFB (0.40) | CBFBNPBWR1DGAT1KCNH2BACE1 | |
| SCHEMBL5213900 | 0.70 | KIT (0.54) | CBFBNPBWR1DGAT1KCNH2BACE1 | |
| SCHEMBL27967806 | 0.69 | TAAR1 (0.50) | — | |
| SCHEMBL28788199 | 0.68 | MEN1 (0.52) | — | |
| SCHEMBL28812710 | 0.68 | MEN1 (0.49) | — | |
| SCHEMBL26111137 | 0.68 | MEN1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CBFB 1560/4885NPBWR1 391/4885DGAT1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.